Selected article for: "action mechanism and comparative study"
Author: Li, Yuping; Shi, Keqing; Qi, Feng; Yu, Zhijie; Chen, Chengshui; Pan, Jingye; Wu, Gaojun; Chen, Yanfang; Li, Ji; Chen, Yongping; Zhou, Tieli; Li, Xiaokun; Xia, Jinglin
Title: Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study
  • Cord-id: 293b8quf
  • Document date: 2020_12_14
    • ID: 293b8quf
    Snippet: OBJECTIVES: The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms. METHODS: A nonrandomized comparative case series study was performed. Six patients received thalidomide 100 mg per day (with therapy lasting for ≥7 days) plus low-dose short-term dexamethasone, and 6 control patients matched with patients in the thalidomide group, received low-dose
    Document: OBJECTIVES: The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms. METHODS: A nonrandomized comparative case series study was performed. Six patients received thalidomide 100 mg per day (with therapy lasting for ≥7 days) plus low-dose short-term dexamethasone, and 6 control patients matched with patients in the thalidomide group, received low-dose short-term treatment with dexamethasone alone. The main outcomes were: the duration of SARS-CoV-2 negative conversion from admission; length of hospital stay; and changes in inflammatory cytokine concentrations and lymphocyte subsets. RESULTS: The median thalidomide treatment time was 12.0 days. The median duration of SARS-CoV-2 negative conversion from admission and hospital stay length were briefer in the thalidomide group compared to the control group (respectively, 11.0 vs 23.0 days, P = 0.043; 18.5 vs 30.0 days, P = 0.043). The mean reduction rates at 7–10 days after treatment for serum interleukin-6 and interferon-γ concentrations were greater in the thalidomide group compared to the control group. Alterations in lymphocyte numbers in the subsets between the 2 groups were similar. CONCLUSIONS: Thalidomide plus short-term glucocorticoid therapy is an effective and safe regimen for the treatment of severely ill COVID-19 patients. The mechanism of action is most likely inhibition of inflammatory cytokine production.

    Search related documents:
    Co phrase search for related documents
    • absolute count and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • absolute count and low dose dexamethasone: 1
    • absolute count and low dose dexamethasone therapy: 1
    • absolute lymphocyte count and acute ards respiratory distress syndrome: 1, 2
    • absolute lymphocyte count and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absolute relative and acute ards respiratory distress syndrome: 1
    • absolute relative and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • absolute relative and additional study: 1
    • acid level and acute ards respiratory distress syndrome: 1, 2, 3
    • acid level and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and local centers: 1
    • acute ards respiratory distress syndrome and low dose dexamethasone: 1, 2
    • acute sars cov respiratory syndrome coronavirus and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute sars cov respiratory syndrome coronavirus and local centers: 1
    • acute sars cov respiratory syndrome coronavirus and lopinavir arbidol: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute sars cov respiratory syndrome coronavirus and lopinavir arbidol antiviral: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and low dose dexamethasone: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and low dose dexamethasone therapy: 1, 2